At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
QBX258 +1 moredrug
Likely dose
QBX258 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-blind Multiple-dose Placebo-controlled Trial to Establish the Efficacy of QBX258 (Combination of VAK694 and QAX576) in Asthma That is Inadequately Controlled With Inhaled Corticosteroids and Long Acting Beta Agonists
In Brief
A Phase 2 clinical trial evaluating QBX258 and Placebo for Asthma. Completed, enrolled 65 participants across 20 sites in 3 countries.
Detailed Summary
This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesGermany, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartFeb 2012
Primary CompletionFeb 2015
TodayJul 2026
First PostedNov 24, 2011
Enrollment StartFeb 1, 2012
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 14.6 years ago
Interventions
QBX258drug
QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
Placebodrug
The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.